Avalyn Pharma advances inhaled pirfenidone AP01 in Phase 2b MIST trial for progressive pulmonary fibrosis

Avalyn Pharma will present two posters at the ERS Congress 2026 in Barcelona, highlighting patient perspectives on IPF trial participation and modeling data for its nebulized pirfenidone program, AP01. The company confirmed that AP01 is currently in a global Phase 2b trial for progressive pulmonary fibrosis, with prior studies supporting its tolerability. Additionally, Avalyn's pipeline includes an inhaled nintedanib program in Phase 2 for IPF.

Avalyn Pharma slated two ERS Congress 2026 posters on Sept. 7 in Barcelona, spotlighting patient trial participation perspectives in IPF. * Second presentation will preview modeling work suggesting its nebulized pirfenidone program, AP01, can distribute broadly across the lung. * Results will be presented in the future at the congress, not previously disclosed in this announcement. * AP01 remains in a global Phase 2b trial in progressive pulmonary fibrosis, with prior studies described as supportive of tolerability. * Pipeline also includes inhaled nintedanib in Phase 2 for IPF, with a fixed-dose combination program positioned as a longer-term strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608241601PRIMZONEFULLFEED9814422) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

AVLN